Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14329951 | 0.88 | AKT1 (0.51) | AKT1CNR1CNR2AKT2 | |
| SCHEMBL14975634 | 0.86 | CNR1 (0.50) | AKT1CNR1CNR2AKT2 | |
| SCHEMBL14329960 | 0.85 | AKT1 (0.64) | AKT1CNR1CNR2AKT2CYP2C9 | |
| SCHEMBL14977636 | 0.84 | AKT1 (0.48) | AKT1CNR1CNR2AKT2CYP3A4 | |
| SCHEMBL14329958 | 0.84 | AKT1 (0.48) | AKT1ITGB1ITGA4CNR1CNR2 | |
| SCHEMBL30446264 | 0.83 | AKT1 (0.81) | AKT1AKT2CYP3A4CYP2C9 | |
| SCHEMBL12419899 | 0.83 | AKT1 (0.81) | AKT1AKT2CYP3A4CYP2C9 | |
| SCHEMBL14976591 | 0.83 | AKT1 (0.46) | AKT1CNR1CNR2AKT2CYP3A4 | |
| SCHEMBL14329954 | 0.82 | AKT1 (0.46) | AKT1CNR1CNR2AKT2 | |
| SCHEMBL14976492 | 0.82 | CYP1A2 (0.49) | AKT1CNR1CNR2AKT2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013078254-A1 | BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-05-30 | — | — | WO | disclosed |